Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garsorasib (D-1553) in KRAS G12C-mutated Pancreatic Cancer
CTR20244442Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in pancreatic cancer (PC), sponsored by EpimAb Biotherapeutics. Started Nov 2024; status: terminated.
02
Drugs
garsorasib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20244442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244442.